제목 BSC-1401(Immuno-Oncology)
작성자 bisichem
작성일자 2021-04-08

BiSiChem is developing TGF-β inhibitors as a candidate for solid tumors and/or immunotherapy

and applied for the PCT international patent in 2020.

TGF-β Inhibitor relates to a series of substituted heterocyclic compounds which are inhibitors

of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4).

The inhibitor plays a key role in improving the surrounding environment to ensure that immune cells attack cancer cells.


In normal cells, TGF-β plays a crucial role in the maintenance of cell homeostasis and organ formation,

including cell growth & death, differentiation, immunity and epithelial-mesenchymal transition(EMT)

in various biological processes.

However, abnormal signal transduction of TGF-β causes life-threatening diseases such as cancer, fibrosis,

NASH, and diabetes. Especially in the tumor micro environment, it suppresses immunity, promotes cancer cell metastasis,

and induces anti-cancer drugs resistance.